Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **topical combination treatment** for acne vulgaris that consists of three active components: **clascoterone**, **clindamycin**, and **benzoyl peroxide**. - **Clascoterone** is a topical androgen receptor antagonist that reduces sebum production and inhibits androgen-driven inflammation in the skin. - **Clindamycin** is a topical antibiotic that inhibits bacterial protein synthesis and reduces levels of *Cutibacterium acnes* (the bacteria implicated in acne). - **Benzoyl peroxide** is a topical antimicrobial and keratolytic agent that reduces bacterial load, helps prevent antibiotic resistance, and promotes exfoliation of the skin. This combination is designed to target multiple pathogenic pathways in acne: androgen-driven sebum production, bacterial colonization, inflammation, and follicular hyperkeratinization. No unique brand or code name is currently attributed to this specific three-drug combination; the constituents may be used together as separate products in practice[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clascoterone + clindamycin + benzoyl peroxide.